Apogee Therapeutics prices public offering of 5M shares at $70, net ~$377.4M

Apogee Therapeutics, Inc.

5,000,000 shares offered at $70 per share; underwriters' option for 750,000 shares exercised in full.
Net proceeds expected ~$377.4M after underwriting discounts and commissions and estimated expenses.
Offering expected to close March 26, 2026; underwriters include Jefferies, TD Securities, Stifel, Guggenheim.
Shares sold under shelf registration statement (File No. 333-281503) effective August 12, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Apogee Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC valued at $70.00 per share (effective 2026-03-24).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC
Value: $70.00 per share
Effective: 2026-03-24

Exact text from the filing

On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the Underwriters named therein (the “Underwriters”), to issue and sell 5,000,000 shares of the Company’s common stock at a public offering price of $70.00 per share (the “Offering”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-034579

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.